Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:57:38.274Z.
Calculation as of: 2026-10-06T19:57:38.274Z.
Quote observation: 2026-10-06T19:55:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1439c3a9e54fb1f97ae208c5489c534aa692153c8f3b45d8dac24981f451ae3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$22.00M
EV/EBITDA Ratio
N/A
TTM Avg
6.88x
3Y Avg
5.95x
5Y Avg
5.95x
Market Cap
$23.26M
EV/EBITDA Ratio
N/A
TTM Avg
0.53x
3Y Avg
0.52x
5Y Avg
0.52x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LeonaBio, Inc. (LONA) | $22.50M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A | 6.88x | 5.95x | 5.95x |
| Rein Therapeutics Inc. (RNTX)vs › | $22.92M | N/A | N/A | N/A | N/A |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.26M | N/A | 0.53x | 0.52x | 0.52x |
| Kyntra Bio, Inc. (KYNB)vs › | $23.92M | N/A | 70.33x | 70.33x | 70.33x |
| NextCure, Inc. (NXTC)vs › | $19.45M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.16M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.59M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.91M | N/A | 11456.84x | 11456.84x | 11456.84x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
